Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019.
Hiroaki OgataTaisuke NakagawaSoichiro SakodaAkiko IshimatsuKazuhito TaguchiMasako KadowakiAtsushi MoriwakiMakoto YoshidaPublished in: Respirology case reports (2021)
A 78-year-old Japanese woman with no smoking history suffered from near-fatal coronavirus disease 2019 (COVID-19) requiring four-week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high-flow nasal cannula oxygen therapy. In parallel with tapering systemic steroid, the patient was treated with nintedanib. Three months later, the patient was able to walk with a walking aid using oxygen at 4 L/min. The present case is an indication that nintedanib might provide a novel therapeutic approach for managing post-COVID-19 fibrosis, although further studies are warranted.
Keyphrases
- coronavirus disease
- pulmonary fibrosis
- mechanical ventilation
- idiopathic pulmonary fibrosis
- case report
- interstitial lung disease
- acute respiratory distress syndrome
- respiratory failure
- respiratory syndrome coronavirus
- intensive care unit
- extracorporeal membrane oxygenation
- high intensity
- sars cov
- systemic sclerosis
- high dose
- physical activity
- clinical trial
- obstructive sleep apnea
- lower limb
- body composition